Table 1

Clinical characteristics of the SLE patients according to ACR criteria and presence of cardiovascular events at any time during disease

Cohort I (n = 10)Cohort II (n = 69)
Malar rash, % 30 61 
Discoid rash, % 20 30 
Photosensitivity, % 40 64 
Oral ulcers, % 10 30 
Arthritis, % 50 81 
Serositis, % 40 65 
Renal disease, % 50 42 
Neurologic disorder, % 10 
Hematologic manifestations, % 70 52 
Leukopenia, % 70 39 
Lymphopenia, % 60 28 
Thrombocytopenia, % 20 20 
Immunology, % 80 67 
ANA, % 100 100 
Anti-DNA antibodies, % 90 71 
Anti-cardiolipin antibodies, % 50 45 
Anti-phospholipid antibody syndrome, % 20 29 
Vascular disease, % 10 45 
Median time since event, y (range) 24 8 (2-36) 
Venous thrombosis, % 10 29 
Median time since event, y (range) 24 16 (3-36) 
Arterial thrombosis, % 19 
Median time since event, y (range)  8 (1-18) 
Myocardial infarction, % 15 
Median time since event, y (range)  7 (2-30) 
Cohort I (n = 10)Cohort II (n = 69)
Malar rash, % 30 61 
Discoid rash, % 20 30 
Photosensitivity, % 40 64 
Oral ulcers, % 10 30 
Arthritis, % 50 81 
Serositis, % 40 65 
Renal disease, % 50 42 
Neurologic disorder, % 10 
Hematologic manifestations, % 70 52 
Leukopenia, % 70 39 
Lymphopenia, % 60 28 
Thrombocytopenia, % 20 20 
Immunology, % 80 67 
ANA, % 100 100 
Anti-DNA antibodies, % 90 71 
Anti-cardiolipin antibodies, % 50 45 
Anti-phospholipid antibody syndrome, % 20 29 
Vascular disease, % 10 45 
Median time since event, y (range) 24 8 (2-36) 
Venous thrombosis, % 10 29 
Median time since event, y (range) 24 16 (3-36) 
Arterial thrombosis, % 19 
Median time since event, y (range)  8 (1-18) 
Myocardial infarction, % 15 
Median time since event, y (range)  7 (2-30) 

SLE indicates systemic lupus erythematosus; and ACR, American College of Rheumatology.

Close Modal

or Create an Account

Close Modal
Close Modal